Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post on X:
“delphi303 at ESMO 2025 phase1b study acceptable toxicity very promising OS benefit compared to SoC,TBC in late phase trials to drive a revolution in small cell lung cancer treatment.
Terrific discussion of context by Noemi Reguart.”
More posts about EMUC25 on OncoDaily.
